Great Lakes Advisors LLC Has $3.48 Million Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Great Lakes Advisors LLC lifted its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 130.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 379,187 shares of the medical technology company’s stock after purchasing an additional 214,375 shares during the quarter. Great Lakes Advisors LLC owned 0.27% of Alphatec worth $3,481,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of ATEC. R Squared Ltd acquired a new stake in Alphatec in the 4th quarter valued at approximately $29,000. Nisa Investment Advisors LLC raised its position in Alphatec by 973.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock valued at $43,000 after buying an additional 4,234 shares during the last quarter. Newton One Investments LLC acquired a new stake in Alphatec in the 4th quarter valued at approximately $50,000. XTX Topco Ltd acquired a new stake in Alphatec in the 3rd quarter valued at approximately $69,000. Finally, AlphaQuest LLC acquired a new stake in Alphatec in the 4th quarter valued at approximately $80,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

Alphatec Stock Up 0.2 %

ATEC stock opened at $9.29 on Friday. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The firm has a market capitalization of $1.34 billion, a PE ratio of -7.26 and a beta of 1.39. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $14.88. The business’s 50 day simple moving average is $10.95 and its 200 day simple moving average is $8.70.

Alphatec (NASDAQ:ATEC) last posted its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). The business had revenue of $176.79 million for the quarter, compared to analyst estimates of $172.74 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. As a group, research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Insider Buying and Selling

In related news, CEO Patrick Miles sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $12.03, for a total transaction of $601,500.00. Following the transaction, the chief executive officer now directly owns 6,152,544 shares of the company’s stock, valued at approximately $74,015,104.32. The trade was a 0.81 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David Sponsel sold 58,283 shares of the company’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $10.71, for a total value of $624,210.93. Following the completion of the transaction, the executive vice president now directly owns 502,311 shares in the company, valued at approximately $5,379,750.81. This represents a 10.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 337,321 shares of company stock valued at $3,828,060. 22.80% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on ATEC shares. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research report on Tuesday, January 14th. Barclays lifted their target price on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, January 22nd. StockNews.com upgraded Alphatec from a “sell” rating to a “hold” rating in a research note on Friday, February 28th. Piper Sandler raised their price target on Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. Finally, Needham & Company LLC restated a “buy” rating and issued a $16.00 price target on shares of Alphatec in a research note on Thursday, February 27th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $17.67.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.